Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk

Patient reminder cards about the risk of osteonecrosis of the jaw are being introduced; denosumab 120 mg is now contraindicated in patients with unhealed lesions from dental or oral surgery.

 

Latanoprost (Xalatan): increased reporting of eye irritation since reformulation

Advise patients to tell their health professional if they experience severe eye irritation.

 

New Yellow Card app for reporting suspected side effects

A new smartphone app for reporting side effects to the Yellow Card Scheme has now launched.

 

Letters sent to healthcare professionals in June 2015

Last month, letters sent included one for the oral anticoagulant edoxaban.

 

 

Posted on the UK MHRA website on 20 June 2015